Literature DB >> 31030866

Temporal Trends of Women Enrollment in Major Cardiovascular Randomized Clinical Trials.

Inna Y Gong1, Nigel S Tan2, Sammy H Ali3, Gerald Lebovic4, Muhammad Mamdani5, Shaun G Goodman6, Dennis T Ko7, Andreas Laupacis8, Andrew T Yan9.   

Abstract

BACKGROUND: Although it is known that women do not participate in trials as frequently as men, there are limited recent data examining how women recruitment has changed over time.
METHODS: We conducted MEDLINE search using a validated strategy for randomized trials published in New England Journal of Medicine, Lancet, and Journal of the American Medical Association between 1986 and 2015, and included trials evaluating pharmacologic or nonpharmacologic therapies. We abstracted data on demographics, intervention type, clinical indication, and trial design characteristics, and examined their relationships with women enrollment.
RESULTS: In total, 598 trials met inclusion criteria. Women enrollment increased significantly over time (21% between 1986 and 1990 to 33% between 2011 and 2015; Pfor trend < 0.001) and did not differ by journal or funding source. Women enrollment varied with clinical indication, comprising 37% for non-coronary artery disease vascular trials, 30% for coronary artery disease trials, 28% for heart failure trials, and 28% for arrhythmia trials (P < 0.001), which were all significantly lower than the expected proportion in disease populations (P < 0.001). Women enrollment varied with trial type (31%, 29%, and 26% for pharmacologic, device, and procedural trials, respectively; P = 0.001). These findings were corroborated using multivariable analysis. We found significant positive correlations between women enrolled, and mean age and total number of participants. Fewer women were enrolled in trials reporting statistically significant results than those who did not (P = 0.001).
CONCLUSIONS: Although enrollment of women has increased over time, it remains lower than the relative proportion in the disease population. Future studies should elucidate the reasons for persistent under-representation of women in clinical trials.
Copyright © 2019 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2019        PMID: 31030866     DOI: 10.1016/j.cjca.2019.01.010

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  15 in total

1.  Women with Myocardial Infarction Present Subtle Cognitive Difficulties on a Neuropsychological Battery After Exposure to a Social Stressor.

Authors:  Marilou Poitras; Nicolás Francisco Narvaez Linares; Maude Lambert; Jeffrey N Browndyke; Hélène Plamondon
Journal:  Psychol Res Behav Manag       Date:  2022-09-23

Review 2.  Disparities in Cardio-oncology: Effects On Outcomes and Opportunities for Improvement.

Authors:  Javaria Ahmad; Anjani Muthyala; Ashish Kumar; Sourbha S Dani; Sarju Ganatra
Journal:  Curr Cardiol Rep       Date:  2022-06-27       Impact factor: 3.955

3.  Trends in Women's Leadership of Oncology Clinical Trials.

Authors:  Ithai Waldhorn; Ayelet Dekel; Anna Morozov; Elisa Sardas Alon; Danielle Stave; Noam Ben Tsrooya; Shir Schlosser; Gal Markel; David Bomze; Tomer Meirson
Journal:  Front Oncol       Date:  2022-06-08       Impact factor: 5.738

Review 4.  Are we any WISER yet? Progress and contemporary need for smart trials to include women in coronary artery disease trials.

Authors:  Ana Iribarren; Márcio Augusto Diniz; C Noel Bairey Merz; Chrisandra Shufelt; Janet Wei
Journal:  Contemp Clin Trials       Date:  2022-04-20       Impact factor: 2.261

5.  Prediction of (Non)Participation of Older People in Digital Health Research: Exergame Intervention Study.

Authors:  Arianna Poli; Susanne Kelfve; Leonie Klompstra; Anna Strömberg; Tiny Jaarsma; Andreas Motel-Klingebiel
Journal:  J Med Internet Res       Date:  2020-06-05       Impact factor: 5.428

6.  Sex Proportionality in Pre-clinical and Clinical Trials: An Evaluation of 22 Marketing Authorization Application Dossiers Submitted to the European Medicines Agency.

Authors:  Marieke J H J Dekker; Sieta T de Vries; Carolien H M Versantvoort; Ellen G E Drost-van Velze; Mansi Bhatt; Peter J K van Meer; Ineke K Havinga; Christine C Gispen-de Wied; Peter G M Mol
Journal:  Front Med (Lausanne)       Date:  2021-03-11

Review 7.  Sex, Race, and Age Differences in Cardiovascular Outcomes in Implantable Cardioverter-Defibrillator Randomized Controlled Trials: A Systematic Review and Meta-analysis.

Authors:  Mohammad K Syed; Hassan I Sheikh; Bradley McKay; Nicholas Tseng; Maureen Pakosh; Jessica E Caterini; Abhinav Sharma; Tracey J F Colella; Kaja M Konieczny; Kim A Connelly; Michelle M Graham; Michael McDonald; Laura Banks; Varinder Kaur Randhawa
Journal:  CJC Open       Date:  2021-09-24

8.  Impact of dedicated women's outreach workers (WOWs) on recruitment of women in ACTG clinical studies.

Authors:  Elizabeth Barr; Karine Dubé; Shobha Swaminathan; Carlos Del Rio; Danielle M Campbell; Marta Paez-Quinde; Susan E Cohn
Journal:  HIV Res Clin Pract       Date:  2021-06-18

9.  Recruitment, experience, and retention among women with HIV and hazardous drinking participating in a clinical trial.

Authors:  Shantrel S Canidate; Christa L Cook; Deepthi Varma; Giselle D Carnaby; Nicole Ennis; Nichole E Stetten; Robert L Cook
Journal:  BMC Public Health       Date:  2020-07-27       Impact factor: 4.135

Review 10.  Disparities in Cardiovascular Care and Outcomes for Women From Racial/Ethnic Minority Backgrounds.

Authors:  Sujana Balla; Sofia Elena Gomez; Fatima Rodriguez
Journal:  Curr Treat Options Cardiovasc Med       Date:  2020-11-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.